c-Myc downregulation: A critical molecular event in resveratrol-induced cell cycle arrest and apoptosis of human medulloblastoma cells

Journal of Neuro-Oncology

Volumn 80, Issue 2, 2006, Pages 123-131

  Zhang, Peng ^a   Li, Hong ^a   Wu, Mo Li ^a   Chen, Xiao Yan ^a   Kong, Qing You ^a   Wang, Xiao Wei ^a   Sun, Yuan ^a   Wen, Shu ^a   Liu, Jia ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; c Myc; Cellcycle; Differentiation; Medulloblastoma; Resveratrol

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MYC PROTEIN; RESVERATROL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL GROWTH; CELL POPULATION; CELL SURVIVAL; CEREBELLUM; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MEDULLOBLASTOMA; MOLECULAR GENETICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTIOXIDANTS; APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENES, MYC; HUMANS; IMMUNOHISTOCHEMISTRY; MEDULLOBLASTOMA; NEOPLASM PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; S PHASE; STILBENES; TRANSFECTION;

EID: 33750358736     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-006-9172-7     Document Type: Article

References (46)

1. Boughton B (2002) Childhood cancer treatment causes complications later in life. Lancet Oncol 3:390
2. Ehrlich PF, Lamkin T (2003) Unusual delayed complication of central venous access. J Pediatr Hematol Oncol 23:472-473
3. Liu J, Guo L, Li JW, Liu N, Li H (2000) All- trans retinoic acid modulates fas expression and enhances chemosensitivity of human medulloblastoma cells. Int J Mol Med 5:145-149
4. Liu J, Guo L, Lou Y, Li JW, Li H (2000) All- trans retinoic acid suppresses in vitro growth and down-regulates LIF gene expression as well as telomerase activity of human medulloblastoma cells. Anticancer Res 20:2659-2664
5. Soleas GJ, Diamandis EP, Goldberg DM (1997) Resveratrol: A molecule whose time has come? And gone? Clin Biochem 30:91-113
6. Sanders TH, Mcmichael RW, Hendrix KW (2000) Occurrence of resveratrol in edible peanuts. J Agric Food Chem 48:1243-1246
7. Jang M, Cai L, Udeani GO, Slowing KV (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218-220
8. Kundu JK, Surh YJ (2004) Molecular basis of chemoprevention by resveratrol: NF-kappaB and AP-1 as potential targets. Mutat Res 555:65-80
9. Wang Q, Li H, Wang XW, Wu DC, Chen XY, Liu J (2003) Resveratrol promotes differentiation and induces Fas-independent apoptosis of medulloblastoma cells. Neurosci Lett 351:83-86
10. McManus ME, Burgess WM, Veronese ME, Huggett A, Quattrochi LC, Turkey RH (1990) Metabolism of 2-acetylaminofluorene and benzo(α)pyrene and activation of food-derived heterocyclic amine mutagens by human cytochromes P450. Cancer Res 50:3367-3376
11. Shimada T, Oda Y, Gillam EMJ, Guengerich P, Inoue K (2001) Metabolic activiation of polycyclic aromatic hydrocarbons and other procarcinogens by cytochromes P450 1A1 and P450 1B1 allelic variant and other human cytochromes P450 in Salmonella typhimurium. Drug Metab Dispos 29:1176-1182
12. Liu J, Wang Q, Wu DC, Wang XW, Sun Y, Chen XY, Zhang KL, Li H (2004) Differential regulation of CYP1A1 and CYP1B1 expression in resveratrol-treated human medulloblastoma cells. Neurosci Lett 363:257-261
13. Wu ML, Li H, Wu DC, Wang XW, Wang XY, Chen XY, Kong QY, Ma JX, Gao Y, Li H (2005) CYP1A1 and CYP1B1 expressions in medulloblastoma cells are AhR-independed and have no direct link with resveratrol-induced differentiation and apoptosis. Neurosci Lett 284:33-37
14. Alvaro JO, Maria KM, John MS (1999) Mysterious liaison: The relationship between c-Myc and the cell cycle. Oncogene 18:2934-2941
15. 2 phase of the cell cycle. Mol Cell Biol 21:4929-4937
16. Smith AG, Popov N, Imreh M, Axelson H, Henriksson M (2004) Expression and DNA-binding activity of MYCN/Max and Mnt/Max during induced differentiation of human neuroblastoma cells. J Cell Biochem 92:1282-1295
17. Miyazaki T, Liu ZJ, Kawahara A, Minami Y, Yamada K (1995) Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation. Cell 81:223-231
18. Pelengaris S, Khan M, Evan G (2002) C-Myc: More than just a matter of life and death. Nat Rev Cancer 2:764-776
19. Hoffman B, Amanullah A, Shafarenko M, Liebermann DA (2002) The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene 21:3414-3421
20. Scheurlen WG, Schwabe GC, Joos S, Mollenhauer J, Sorensen N, Kuhl J (1998) Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol 16:2478-2485
21. Grotzer MA, Hogarty MD, Janss AJ, Liu X, Zhao H, Eggert A (2001) C-myc expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 7:2425-2433
22. Richert CH (2004) Prognosis-related molecular markers in pediatric central nervous system tumors. J Neuropathol Exp Neurol 63:1211-1224
23. Keles GE, Berger MS, Srinivasan J, Kolstoe DD, Bobola MS, Silber JR (1995) Establishment and characterization of four human medulloblastoma-derived cell lines. Oncol Res 7:493-503
24. Watson PH, Pon RT, Shiu RPC (1991) Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res 51:3996-4000
25. Whelan HT, Krouwer HG, Schmidt MH, Reichert KW, Kovnar EH (1998) Current therapy and new perspectives in the treatment of medulloblastoma. Pediatr Neurol 18:103-115
26. Mulhern K., Merchant TE, Gajjar A, Reddick WE, Kun LE (2004) Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 5:399-408
27. Packer RJ, Goldwein J, Nicholson HS (1999) Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuwant chemotherapy: A Children's Cancer Group Study. J Clin Oncol 17:2127-2136
28. Palmer SL, Goloubeva O, Reddick WE (2001) Patterns of intellectual development among survivors of pediatric medulloblastoma: A longitudinal analysis. J Clin Oncol 19:2302-2308
29. MacDonald TJ, Rood BR, Santi MR, Vezina G, Bingaman K, Cogen PH, Packer RJ (2003) Advances in the Diagnosis, molecular genetic, and treatment of pediatric embryonal CNS tumors. Oncologist 8:174-186
30. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML (1999) Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 286:531-537
31. Gilbertson R, Wickramasinghe C, Hernan R (2001) Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 85:705-712
32. Michiels EMC, Oussoren E, Van Groenigen M, Pauws E, Bossuyt PMM, Voute PA, Baas F (1999) Genes differentially expressed in medulloblastoma and fetal brain. Physiol Genomics 1:83-91
33. Korenberg MJ (2003) Gene expression monitoring accurately predicts medulloblastoma positive and negative clinical outcome. FEBS Lett 533:110-114
34. Chopra A, Brown KM, Rood BR, Packer RJ, MacDonald TJ (2003) The use of gene expression analysis to gain insights into signaling mechanisms of metastatic medulloblastoma. Pediatric Neurosurg 39:68-74
35. Korshunov A, Savostikova M, Ozerov S (2002) Immunohistochemical markers for prognosis of average-risk pediatric medulloblastomas: The effect of apoptotic index, TrkC, and c-myc expression. J Neurooncol 58:271-279
36. Ramachandran C, Khativ Z, Escalon E, Fonseca HB, Jhabvala P, Medina LS (2002) Molecular studies in pediatric medulloblastomas. Brain Tumor Pathol 19:15-22
37. Fruhwald MC, O'Dorisio MS, Rush LJ, Reiter JL (2000) Gene amplification in PNETs/medulloblastomas: Mapping of a novel amplified gene within the MYCN amplicon. J Med Genet 37:501-509
38. Herms J, Neidt I, Luscher B, Sommer A, Schurmann P, Schroder T (2000) C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer 89:395-402
39. Siu IM, Lal A, Blankenship JR, Aldosari N, Riggins GJ (2003) c-Myc promoter activation in medulloblastoma. Cancer Res 63:4773-4776
40. Eberhart CG, Kratz J, Wang Y, Summers K, Stearns D, Cohen K (2004) Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 63:441-449
41. Chi SN, Gardner SL, Levy AS, Knopp EA, Miller DC, Wisoff JH, Weiner HL, Finlay JL (2004) Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J Clin Oncol 22:4881-4887
42. Tabori U, Sung L, Hukin J, Laperriere N, Crooks B, Carret AS (2005) Medulloblastoma in the second decade of life: A specific group with respect to toxicity and management: A Canadian Pediatric Brain Tumor Consortium Study. Cancer 103:1874-1880
43. Bhat KP, Pezzuto JM (2002) Cancer chemopreventive activity of resveratrol. Ann NY Acad Sci 957:210-229
44. Wolter F, Turchanowa L, Stein J (2003) Resveratrol-induced modification of polyamine metabolism is accompanied by induction of c-Fos. Carcinogenesis 24:469-474
45. Yin X, Landay MF, Han W, Levitan ES, Watkins SC, Levenson RM, Farkas DL, Prochownik EV (2001) Dynamic in vivo interactions among Myc network members. Oncogene 20:4650-4664
46. Mariadason JM, Nicholas C, L'Italien KE, Zhuang M, Smartt HJ, Heerdt BG (2005) Gene expression profiling of intestinal epithelial cell maturation along the crypt-villus axis. Gastroenterology 128:1081-1088